MedTrace Logo

The Tolerability and Pharmacokinetics Study of HEC110114 Tablets in Healthy Adult Subjects

NCT03903081 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 93

Last updated 2020-03-18

No results posted yet for this study

Summary

A Phase I, Single Center, Randomized, Double-blind, Placebo-controlled, Single \& Multiple Ascending Dose Study to Access the Tolerability and Pharmacokinetics of HEC110114 Tablets in Healthy Adult Subjects

Conditions

  • Chronic Hepatitis C

Interventions

DRUG

HEC110114 tablet

administered orally once daily

DRUG

Placebo Oral Tablet

Placebo will be administered orally at a dose and frequency matched to HEC110114

Sponsors & Collaborators

  • Sunshine Lake Pharma Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yanhua Ding, Doctor · The First Hospital of Jilin University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-03-06
Primary Completion
2019-10-29
Completion
2019-10-29

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03903081 on ClinicalTrials.gov